EICHORCondition: Idiopathic Pulmonary Fibrosis · Sponsor: Boehringer Ingelheim
Identifying biomarkers to predict the clinical course and benefits of therapy early in the course of the disease remains one of the most urgent and relevant challenges to improve overall patient management, to prevent treatment delay or overtreatment. This study is conducted to examine the effect of nintedanib treatment on change in biomarkers indicative of extracellular matrix turnover which have been shown recently to correlate with disease progression. This study further aims to confirm the association of biomarker course during the first three months of treatment and disease progression.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Jasper Summit Research, LLC | Jasper, Alabama, United States | — |
| Western Connecticut Medical Group | Danbury, Connecticut, United States | — |
| St. Francis Medical Institute | Clearwater, Florida, United States | — |
| University of Florida College of Medicine | Jacksonville, Florida, United States | — |
| Minnesota Lung Center | Minneapolis, Minnesota, United States | — |
| The Lung Research Center, LLC | Chesterfield, Missouri, United States | — |
| Clinical Research Solutions | Dayton, Ohio, United States | — |
| Pulmonary Associates of Richmond, Inc. | Richmond, Virginia, United States | — |
| Royal Prince Alfred Hospital | Camperdown, Sydney, New South Wales, Australia | — |
| Concord General Repatriation Hospital -Ambulatory Care Unit | Concord, New South Wales, Australia | — |
| Royal Adelaide Hospital | Adelaide, South Australia, Australia | — |
| The Alfred Hospital | Melbourne, Victoria, Australia | — |
+ 74 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02788474